Offering biomedical innovators the experience, expertise, and funding required for success.
Through the RCT Ventures program, venture capital is provided to start-up or early-stage companies with technologies that have the potential to become significant biomedical products with a definite competitive edge. Learn more ›
RCT develops and invests in technologies that enhance and enable the discovery and manufacture of therapeutics and diagnostics. Many of these life science tools are available from RCT through affordable nonexclusive licensing. Learn more ›
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has submitted a Biologics License Application (BLA) for its candidate shingles vaccine, Shingrix , to the United States Food and Drug Administration (FDA), seeking approval for the prevention of herpes zoster (shingles) … Learn more